Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: November 26, 2022

Details for Patent: 6,211,233

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 6,211,233
Title: Prostaglandin pharmaceutical compositions
Abstract:Compounds of the general formula A--X.sub.1 --NO.sub.2, or their pharmaceutical compositions, wherein A contains a prostaglandin residue, X.sub.1 is a bivalent connecting bridge.
Inventor(s): Del Soldato; Piero (Milan, IT)
Assignee: Nicox S.A. (Paris, FR)
Application Number:09/423,286
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 6,211,233

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,211,233

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI97A001440Jun 19, 1997
PCT Information
PCT FiledJune 17, 1998PCT Application Number:PCT/EP98/03645
PCT Publication Date:December 30, 1998PCT Publication Number: WO98/58910

International Family Members for US Patent 6,211,233

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 225771 See Plans and Pricing
Australia 740683 See Plans and Pricing
Australia 8438698 See Plans and Pricing
Brazil 9810163 See Plans and Pricing
Canada 2292836 See Plans and Pricing
China 1260778 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.